Oncology Biosimilars Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

The global oncology biosimilars market is estimated to grow from US$ 9.2 billion in 2026 to US$ 31.3 billion by 2033. The market is projected to record a CAGR of 19.1% during the forecast period from 2026 to 2033.

The global market is expanding steadily due to rising cancer prevalence, increasing demand for cost-effective biologic therapies, and patent expirations of major oncology biologics. Europe leads the market with strong biosimilar adoption and supportive regulatory frameworks, while Asia-Pacific is the fastest-growing region, driven by expanding healthcare access, local biosimilar manufacturing, and increasing cancer treatment demand.